Alpha-enolase specific antibodies and methods of uses in cancer therapy
US9382331B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 27, 2013 |
| Grant date | Jul 5, 2016 |
| Priority date | — |
| Expiry date | Dec 27, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/988
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses an anti-human alpha-enolase (ENO1) antibody, which can bind the peptides, comprising amino-acid sequence 296FD Q D D W G A W Q K F TA309 (SEQ ID: #9) and/or 326K R I A K A V N EK S336 (SEQ ID: #10) of human ENO1 protein (GenBank: AAH50642.1), has a favorable binding activity (the binding affinity is around 2.19×10-10 mol/L) and a remarkable capability to inhibit the cell invasion and tumor metastasis of a varied of tumors. The recognized peptides and antibody of the invention are useful for diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface ENO1 such as including lung, breast, pancreas, liver, colorectal, prostate cancers and solid tumors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.